Flavonoids as modulators of metabolic reprogramming in renal cell carcinoma (Review).

IF 3.8 3区医学 Q2 ONCOLOGY Oncology reports Pub Date : 2024-12-01 Epub Date: 2024-10-18 DOI:10.3892/or.2024.8826

Asif Shahzad, Wenjing Liu, Yijian Sun, Xiangjie Liu, Jiaojiao Xia, Kun Cui, Buqing Sai, Yuechun Zhu, Zhe Yang, Qiao Zhang

{"title":"Flavonoids as modulators of metabolic reprogramming in renal cell carcinoma (Review).","authors":"Asif Shahzad, Wenjing Liu, Yijian Sun, Xiangjie Liu, Jiaojiao Xia, Kun Cui, Buqing Sai, Yuechun Zhu, Zhe Yang, Qiao Zhang","doi":"10.3892/or.2024.8826","DOIUrl":null,"url":null,"abstract":"<p><p>Renal cell carcinoma (RCC) is distinguished by its varied metabolic reprogramming driven by tumor suppressor gene dysregulation and oncogene activation. Tumors can adapt nutrient uptake and metabolism pathways to meet the altered biosynthetic, bioenergetic and redox demands of cancer cells, whereas conventional chemotherapeutics and molecular inhibitors predominantly target individual metabolic pathways without addressing this adaptability. Flavonoids, which are well‑known for their antioxidant and anti‑inflammatory properties, offer a unique approach by influencing multiple metabolic targets. The present comprehensive review reveals the intricate processes of RCC metabolic reprogramming, encompassing glycolysis, mitochondrial oxidative phosphorylation and fatty acid biosynthesis. The insights derived from the present review may contribute to the understanding of the specific anticancer mechanisms of flavonoids, potentially paving the way for the development of natural antitumor drugs focused on the metabolic reprogramming of RCC.</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"52 6","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526433/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/or.2024.8826","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Renal cell carcinoma (RCC) is distinguished by its varied metabolic reprogramming driven by tumor suppressor gene dysregulation and oncogene activation. Tumors can adapt nutrient uptake and metabolism pathways to meet the altered biosynthetic, bioenergetic and redox demands of cancer cells, whereas conventional chemotherapeutics and molecular inhibitors predominantly target individual metabolic pathways without addressing this adaptability. Flavonoids, which are well‑known for their antioxidant and anti‑inflammatory properties, offer a unique approach by influencing multiple metabolic targets. The present comprehensive review reveals the intricate processes of RCC metabolic reprogramming, encompassing glycolysis, mitochondrial oxidative phosphorylation and fatty acid biosynthesis. The insights derived from the present review may contribute to the understanding of the specific anticancer mechanisms of flavonoids, potentially paving the way for the development of natural antitumor drugs focused on the metabolic reprogramming of RCC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

类黄酮作为肾细胞癌代谢重编程的调节剂（综述）。

肾细胞癌（RCC）的特点是在肿瘤抑制基因失调和癌基因激活的驱动下进行各种代谢重编程。肿瘤可以调整营养摄取和代谢途径，以满足癌细胞改变的生物合成、生物能和氧化还原需求，而传统的化疗药物和分子抑制剂主要针对单个代谢途径，无法解决这种适应性问题。类黄酮以其抗氧化和抗炎特性而闻名，它通过影响多个代谢靶点而提供了一种独特的方法。本综述揭示了 RCC 代谢重编程的复杂过程，包括糖酵解、线粒体氧化磷酸化和脂肪酸生物合成。本综述所得出的见解可能有助于人们了解黄酮类化合物的特定抗癌机制，从而为开发专注于 RCC 代谢重编程的天然抗肿瘤药物铺平道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oncology reports 医学-肿瘤学

CiteScore

8.50

自引率

2.40%

发文量

187

审稿时长

3 months

期刊介绍： Oncology Reports is a monthly, peer-reviewed journal devoted to the publication of high quality original studies and reviews concerning a broad and comprehensive view of fundamental and applied research in oncology, focusing on carcinogenesis, metastasis and epidemiology.